Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patients own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
April 3, 2020
RegMed Investors’ (RMi) pre-open: suspicion of yesterday’s upside
April 2, 2020
RegMed Investors’ (RMi) closing bell: What is not priced in?
April 1, 2020
RegMed Investors’ (RMi) closing bell: the cell/gene sector baby programs are being disregarded and tossed with the bathwater
April 1, 2020
RegMed Investors’ (RMi) pre-open: an enduring challenge after market posts the poorest Q1 on record
March 31, 2020
RegMed Investors’ (RMi) closing bell: the cell/gene sector swings neutral as Q1 ends and markets collapse
March 31, 2020
RegMed Investors’ (RMi) pre-open: as the quarter ends, don’t chase the sector’s pricing
March 30, 2020
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector moves to the upside and stays there
March 27, 2020
RegMed Investors’ (RMi) closing bell: volatility strikes to the heart of cell/gene therapy sector and its sentiment indicator
March 27, 2020
RegMed Investors’ (RMi) pre-open: I’m worried about share pricing sustainability
35 companies, 1 interpreter!
Insight, foresight and recommendation
Vericel (VCEL) – Opened 1/2/18 at $5.90, saw a high of $7.30; started February at $8.15 slipping with a low of $6.60 and started March at $8.05 jumping to $11.35 on $3/6 after announcing a $300 K net incomeand a per share value of +$0.01. Further thoughts rflect strong use of an ATM and at this "peak" - a financing "could" ensue ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.